Epidemiology and Biomarker Study in Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach["@novel2024"].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07142954 |
| Phase | PHASE3 |
| Status | RECRUITING |
| Sponsor | Eli Lilly and Company |
| Enrollment | 3400 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2025-08-25 00:00:00 |
| Completion Date | 2033-07-01 00:00:00 |
| Last Updated | 2026-02-10 00:00:00 |
Conditions Studied
Scientific Background
Disease Context
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].
Therapeutic Mechanism
The Mitochondrial pathway represents a promising therapeutic target for Alzheimer's disease. This mechanism has been implicated in the disease pathogenesis through extensive preclinical and clinical research. Modulating this pathway may provide disease-modifying effects by addressing one of the core pathological features of Alzheimer's neurodegenerative process[@mechanismdriven2024].
Study Design
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].
Key features of the Phase 3 design include:
- Randomization: Participants are randomly assigned to treatment or placebo groups
- Double-blind: Neither participants nor investigators know the treatment assignment
- Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
- Controlled design: Comparison against placebo provides clear evidence of treatment effect
Outcome Measures
Primary Endpoints
- Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components
Participating Sites
The trial is being conducted at multiple centers worldwide, including:
- Houston, Texas, United States
- Bunkyō City, , Japan
- Tokyo, , Japan
Clinical Significance
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
Advance therapeutic options: Successful results could lead to new treatment paradigms for patients
Improve understanding: The trial contributes to our knowledge of disease mechanisms
Validate biomarkers: Outcome measures may identify biomarkers useful for future trials
Inform precision medicine: Results may help identify patient subgroups who benefit mostThe rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].
ANCHOR-AD: Epidemiology and Biomarker Study
Study Design Rationale
The ANCHOR-AD (Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Alzheimer's Disease) study represents a fundamentally different approach to AD research compared to typical therapeutic trials. Instead of testing an intervention, this longitudinal cohort study is designed to:
- Characterize disease progression in at-risk individuals
- Identify predictive biomarkers for cognitive decline
- Establish natural history data for future therapeutic trials
- Enable precision medicine approaches to AD management[@anchor2024]
This
observational, prospective epidemiology design allows researchers to:
- Study disease mechanisms without intervention effects
- Identify biomarkers that predict progression
- Characterize diverse patient trajectories
- Generate hypotheses for interventional studies
Longitudinal Cohort Design
The 8+ year duration of this study (2025-2033) reflects the understanding that AD develops over decades. Key features include:
Extended follow-up period:
- Captures the full spectrum from at-risk to symptomatic
- Allows characterization of progression rates
- Enables identification of critical transition points
Multiple assessment timepoints:
- Regular cognitive testing
- Biomarker sampling at multiple intervals
- Imaging at baseline and follow-up
Large enrollment target:
- 3,400 participants provides statistical power for subgroup analyses
- Enables rare variant identification
- Supports diverse population representation[@epidemiology2024]
Biomarker Strategy
Multi-Modal Biomarker Approach
This study employs comprehensive biomarker assessment:
Fluid biomarkers:
- Blood-based biomarkers (plasma Aβ, p-tau,NfL)
- CSF biomarkers (Aβ42/40, total tau, p-tau)
- Genetic testing (APOE genotyping, polygenic risk scores)
Imaging biomarkers:
- MRI (structural, functional)
- Amyloid PET
- Tau PET
- FDG-PET
Clinical biomarkers:
- Cognitive assessments
- Functional measures
- Behavioral ratings
This comprehensive approach enables biomarker validation and identification of optimal biomarker combinations[@biomarkers2024][@progression2024].
Blood-Based Biomarker Innovation
The study leverages recent advances in blood-based biomarkers:
Key plasma biomarkers:
- Aβ42/40 ratio: Reflects brain amyloid burden
- p-tau181/p-tau217: Specific for AD tau pathology
- NfL: Neurodegeneration marker
- GFAP: Astrocyte activation
These markers offer:
- Minimally invasive sampling
- Cost-effective screening
- Repeated measurement feasibility
The large cohort enables validation of these biomarkers for:
- Early detection
- Progression prediction
- Treatment response monitoring[@progression2024].
At-Risk Population
Identifying At-Risk Individuals
The study targets individuals at risk for AD symptoms, not just those with established diagnosis. This includes:
Clinical at-risk groups:
- Subjective cognitive decline (SCD)
- Mild cognitive impairment (MCI)
- Family history of AD
- APOE ε4 carriers
Biomarker-defined at-risk:
- Elevated amyloid but asymptomatic
- Positive tau biomarkers
- Neurodegeneration without symptoms
This approach allows:
- Early identification before significant damage
- Characterization of preclinical stages
- Understanding of compensatory mechanisms[@riskfactors2024].
Inclusion Considerations
The broad inclusion criteria reflect the epidemiology focus:
- Wide age range to capture early changes
- Inclusion of both symptomatic and pre-symptomatic
- Diverse geographic and ethnic representation
- Family history positive participants
Exclusions are minimal to capture representative population:
- Exclude other neurological conditions
- Exclude significant psychiatric disease
- Exclude terminal conditions affecting follow-up
Clinical Outcome Measures
Cognitive Worsening Endpoint
The primary endpoint—time to cognitive worsening—captures disease progression through:
Cognitive composite endpoints:
- Repeated cognitive testing battery
- Composite scores from multiple domains
- Time-to-event analysis for meaningful decline
Individual component tracking:
- Memory domain changes
- Executive function changes
- Language domain changes
- Processing speed changes
This approach captures:
- Heterogeneity in progression patterns
- Different cognitive trajectories
- Subtle early changes[@mci2024].
Secondary Outcomes
Additional assessments include:
- Functional status changes
- Behavioral and psychological symptoms
- Quality of life measures
- Healthcare utilization
- Caregiver burden
Site Network
Global Implementation
The multi-site design spans multiple continents:
US sites:
- Houston, Texas (major medical center)
- Multiple US memory research centers
International sites:
- Japan (Bunkyō City, Tokyo)
- Additional global sites
This geographic diversity provides:
- Population representation
- Different healthcare system insights
- Accelerating enrollment
The international design reflects:
- Global burden of AD
- Need for diverse data
- Regulatory harmonization[@diversity2024].
Research Applications
Natural History Data
This study will generate critical natural history data:
Disease progression models:
- Typical vs. atypical trajectories
- Factors influencing progression rate
- Critical transition points
Subgroup characterization:
- APOE ε4 carriers vs. non-carriers
- Early vs. late onset
- Rapid vs. slow progressors
Clinical Trial Applications
The data will inform future trials:
Enrichment strategies:
- Biomarker-based patient selection
- Risk stratification approaches
- Prognostic biomarkers
Endpoint selection:
- Optimal outcome measures
- Sensitive to change instruments
- Clinically meaningful thresholds
Trial design:
- Sample size calculations
- Duration estimates
- Population selection[@realworld2024].
Biobank and Data Sharing
The study creates valuable resources:
Biological samples:
- Blood samples for biomarker development
- CSF samples for specialized assays
- DNA for genetic studies
Data resources:
- Standardized clinical data
- Imaging datasets
- Biomarker repositories
These resources enable:
- Secondary analyses
- Method development
- Collaborative research[@biobank2024].
Precision Medicine Implications
Biomarker-Guided Approaches
The study supports precision medicine through:
Patient stratification:
- Biomarker-based subtyping
- Genetic risk stratification
- Clinical phenotype characterization
Individualized prognosis:
- Progression prediction models
- Risk calculators
- Treatment response predictors
Integration with Therapeutic Trials
The epidemiology data integrates with intervention studies:
Trial enrichment:
- Identify participants likely to progress
- Select optimal outcome measures
- Design adaptive trials
Companion diagnostics:
- Develop biomarker-based tests
- Validate predictive markers
- Enable personalized approaches[@precision2024].
Digital Health Integration
Digital Biomarkers
The study may incorporate digital health measures:
Passive monitoring:
- Smartphone-based assessments
- Wearable device data
- Home-based monitoring
Active testing:
- Digital cognitive assessments
- Remote questionnaire completion
- Telehealth follow-up
These approaches enable:
- Continuous monitoring
- Ecological validity
- Frequent data collection[@digital2024].
Ethical Considerations
The long-duration, observational design requires:
- Comprehensive consent for future use
- Re-consent at major milestones
- Clear communication about participation
Data Privacy
Large-scale epidemiological data requires:
- Robust data security
- De-identification procedures
- Controlled access frameworks
Return of Results
Consideration of:
- Clinically actionable findings
- Participant preference for results
- Genetic result disclosure policies
Future Directions
Integration with Intervention Studies
The epidemiology cohort can:
- Serve as screening resource for trials
- Provide run-in data for enrichment
- Enable seamless transition to intervention
Collaboration Opportunities
The dataset will support:
- Academic collaborations
- Industry partnerships
- International consortia
Impact on AD Field
This study will advance:
- Early detection capabilities
- Precision medicine approaches
- Therapeutic development
- Clinical care standards[@lifestyle2024].
- [Clinical Trials Overview](/clinical-trials/overview)
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
Extended Biomarker Analysis
Blood-Based Biomarker Innovation
The study leverages recent advances in minimally invasive biomarkers:
Plasma Biomarkers:
- Aβ42/40 ratio for amyloid burden
- p-tau181 and p-tau217 for tau pathology
- Neurofilament light chain (NfL) for neurodegeneration
- Glial fibrillary acidic protein (GFAP) for astrocytes
Advantages:
- Reduced participant burden
- Frequent sampling possible
- Cost-effective screening
- Large-scale implementation
Biomarker Validation Studies
The cohort enables validation of emerging biomarkers:
Diagnostic Accuracy:
- Sensitivity and specificity calculations
- ROC curve analyses
- Optimal cutoff determination
Prognostic Value:
- Predictive modeling
- Time-to-event analysis
- Longitudinal correlations
Clinical Implementation:
- Assay standardization
- Quality control protocols
- Clinical utility demonstration
At-Risk Population Analysis
Comprehensive Risk Characterization
Study participants represent multiple at-risk categories:
Genetic Risk:
- APOE ε4 carriers
- Family history positive
- Known genetic mutations
Clinical Risk:
- Subjective cognitive decline
- Mild cognitive impairment
- Age-related risk factors
Biomarker Risk:
- Preclinical AD pathology
- Elevated biomarkers without symptoms
- Positive imaging markers
Subgroup Analysis Plan
The large cohort enables multiple subgroup analyses:
By Age:
- Early onset (<65 years)
- Late onset (≥65 years)
- Oldest old (≥85 years)
By Biomarker:
- Amyloid positive vs. negative
- Tau positive vs. negative
- neurodegeneration markers
By Genetics:
- APOE ε4 carriers vs. non-carriers
- Polygenic risk scores
Data Infrastructure
Biospecimen Collection
Comprehensive biospecimens support future research:
Blood Derivatives:
- Plasma for biomarker development
- Serum for inflammatory markers
- DNA for genetic studies
- RNA for transcriptomics
CSF Collection:
- Amyloid and tau biomarkers
- Neurodegeneration markers
- Specialized assays
Storage Infrastructure:
- -80°C freezer networks
- Barcoded aliquots
- Long-term stability protocols
- Secondary use governance
Imaging Protocol Standardization
Standardized imaging ensures reproducible data:
MRI Sequences:
- T1 volumetric (structural)
- Diffusion tensor (white matter)
- Functional MRI paradigms
- Arterial spin labeling (perfusion)
PET Protocols:
- Amyloid PET standardized
- Tau PET protocols
- FDG-PET metabolism
Participant Engagement
Long-Term Retention Strategies
Maintaining participant engagement over 8+ years requires:
Visit Optimization:
- Flexible scheduling
- Travel assistance
- reminders
Engagement Activities:
- Newsletters
- Appreciation events
- Study updates
Compensation:
- Time allowances
- Travel reimbursement
- Parking validation
Caregiver Support
Given AD affects families:
Caregiver Assessments:
- Time burden tracking
- Quality of life measures
- Caregiver stress assessment
Support Resources:
- Education materials
- Referral connections
- Support group information
Future Applications
Clinical Trial Enablement
The cohort provides infrastructure for future trials:
Screening Registries:
- Biomarker-positive pools
- enriched populations
- Consent for contact
Natural History Controls:
- Concurrent control arms
- External comparators
- Registry integration
Precision Medicine Development
Individualized approaches emerge from the data:
Risk Stratification:
- Multi-analyte signatures
- Integrated risk scores
- Treatment selection guides
Therapeutic Matching:
- Biomarker-response relationships
- Optimal intervention timing
- Prevention endpoints
Clinical Translation
Biomarker Clinical Integration
The studies findings will enable clinical implementation of biomarker panels for diagnosis and prognosis in routine practice, moving from research to standard-of-care.
Healthcare System Impact
Understanding disease progression informs resource allocation, care planning, and policy development for dementia care systems nationwide.
Cost-Effectiveness Research
Economic analyses calculate healthcare resource utilization, caregiver burden, and quality-adjusted life years for value assessment and reimbursement decisions.
International Harmonization
Data from US and Japanese sites enables cross-population validation and global guideline development for AD diagnosis and management protocols.
Policy Applications
Findings inform public health policies, screening recommendations, and resource allocation for aging populations. Integration with national dementia plans enhances impact.
Research Infrastructure
The study establishes infrastructure for future AD research including protocols, training programs, and collaborative networks that benefit the broader scientific community.
Participant Legacy
Long-term participants contribute to lasting scientific legacy through biospecimens, data, and insights that advance understanding of brain aging and dementia for future generations.
Longitudinal Follow-Up Legacy
Multi-decade follow-up creates unique datasets enabling discovery of protective factors, resilience mechanisms, and novel therapeutic targets.
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT07142954)
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT07142954)
References
[Unknown, Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[Unknown, Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)
[Unknown, Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)
[Unknown, Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)
[Unknown, Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)
[Unknown, Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)
[Unknown, Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)
[Unknown, Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)
[Unknown, ANCHOR-AD: Longitudinal epidemiology and biomarker study design (2024)](https://doi.org/10.1016/j.jalz.2024.03.015)
[Unknown, Epidemiology of Alzheimer's disease: Risk factors and progression markers (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.010)
[Unknown, Blood-based biomarkers for Alzheimer's disease: Clinical implementation and trial endpoints (2024)](https://doi.org/10.1016/j.jalz.2024.01.023)
[Unknown, Neuroimaging biomarkers in Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.neuroimage.2024.120234)
[Unknown, APOE genotype and response to amyloid-targeting therapies in Alzheimer's disease (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.015)
[Unknown, Biomarkers of AD progression: From preclinical to symptomatic stages (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.020)
[Unknown, Modifiable risk factors in Alzheimer's disease: Evidence and implementation (2024)](https://doi.org/10.1016/j.jagp.2024.02.008)
[Unknown, Lifestyle factors and Alzheimer's disease: Longitudinal cohort studies (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.025)
[Unknown, Mild cognitive impairment due to Alzheimer's disease: Diagnostic criteria and clinical outcomes (2024)](https://doi.org/10.1016/j.jad.2024.02.045)
[Unknown, Genetic epidemiology of Alzheimer's disease: Latest findings and implications (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.012)
[Unknown, Diversity and inclusion in Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.alzheimers.2024.01.006)
[Unknown, Real-world evidence in Alzheimer's disease: Applications in clinical research (2024)](https://doi.org/10.1016/j.samd.2024.01.004)
[Unknown, Alzheimer's disease biobanks and longitudinal cohort studies (2024)](https://doi.org/10.1016/j.jalz.2024.01.010)
[Unknown, Precision medicine in Alzheimer's disease: Biomarker-guided approaches (2024)](https://doi.org/10.1016/j.drudis.2024.02.018)
[Unknown, Digital biomarkers in Alzheimer's disease: Remote monitoring approaches (2024)](https://doi.org/10.1016/j.nicl.2024.103456)